Bio-Rad Laboratories Valuation
Is BUWA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BUWA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BUWA (€309.8) is trading above our estimate of fair value (€306.62)
Significantly Below Fair Value: BUWA is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BUWA?
Key metric: As BUWA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BUWA's PS Ratio? | |
|---|---|
| PS Ratio | 3.6x |
| Sales | US$2.58b |
| Market Cap | US$9.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | 18.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BUWA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
SRT3 Sartorius | 4.4x | 9.3% | €13.4b |
1SXP SCHOTT Pharma KGaA | 4.2x | 10.7% | €4.0b |
GXI Gerresheimer | 1.3x | 10.2% | €2.6b |
EVT Evotec | 1.9x | 12.1% | €1.5b |
BUWA Bio-Rad Laboratories | 3.6x | 3.7% | €9.2b |
Price-To-Sales vs Peers: BUWA is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (3x).
Price to Sales Ratio vs Industry
How does BUWA's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BUWA is good value based on its Price-To-Sales Ratio (3.6x) compared to the European Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is BUWA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.6x |
| Fair PS Ratio | 3x |
Price-To-Sales vs Fair Ratio: BUWA is expensive based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €309.80 | €371.27 +19.8% | 13.3% | €432.79 | €290.68 | n/a | 6 |
| Nov ’25 | €327.80 | €366.84 +11.9% | 14.1% | €431.20 | €289.61 | n/a | 6 |
| Oct ’25 | €299.00 | €350.97 +17.4% | 12.0% | €402.92 | €284.57 | n/a | 6 |
| Sep ’25 | €300.00 | €333.20 +11.1% | 10.8% | €384.46 | €281.64 | n/a | 6 |
| Aug ’25 | €311.60 | €342.66 +10.0% | 13.8% | €402.14 | €280.56 | n/a | 5 |
| Jul ’25 | €251.70 | €342.66 +36.1% | 13.8% | €402.14 | €280.56 | n/a | 5 |
| Jun ’25 | €259.50 | €365.53 +40.9% | 12.8% | €408.41 | €278.46 | n/a | 5 |
| May ’25 | €257.40 | €391.64 +52.2% | 6.2% | €411.32 | €340.44 | n/a | 6 |
| Apr ’25 | €323.00 | €401.57 +24.3% | 5.6% | €442.37 | €368.64 | n/a | 6 |
| Mar ’25 | €300.40 | €401.57 +33.7% | 5.6% | €442.37 | €368.64 | n/a | 6 |
| Feb ’25 | €296.00 | €399.12 +34.8% | 6.8% | €446.54 | €364.43 | n/a | 6 |
| Jan ’25 | €290.60 | €395.53 +36.1% | 7.2% | €438.41 | €357.79 | n/a | 6 |
| Dec ’24 | €278.40 | €418.77 +50.4% | 6.1% | €454.00 | €376.76 | n/a | 5 |
| Nov ’24 | €257.80 | €418.77 +62.4% | 6.1% | €454.00 | €376.76 | €327.80 | 5 |
| Oct ’24 | €335.60 | €496.26 +47.9% | 3.4% | €524.10 | €478.24 | €299.00 | 4 |
| Sep ’24 | €365.80 | €494.51 +35.2% | 3.4% | €518.39 | €473.03 | €300.00 | 5 |
| Aug ’24 | €366.80 | €495.53 +35.1% | 5.8% | €538.81 | €464.89 | €311.60 | 5 |
| Jul ’24 | €343.60 | €511.16 +48.8% | 5.3% | €553.03 | €479.90 | €251.70 | 5 |
| Jun ’24 | €346.40 | €516.24 +49.0% | 5.8% | €556.24 | €482.69 | €259.50 | 4 |
| May ’24 | €394.20 | €549.17 +39.3% | 7.9% | €615.47 | €497.81 | €257.40 | 4 |
| Apr ’24 | €430.90 | €574.43 +33.3% | 8.0% | €644.57 | €521.35 | €323.00 | 4 |
| Mar ’24 | €448.80 | €574.43 +28.0% | 8.0% | €644.57 | €521.35 | €300.40 | 4 |
| Feb ’24 | €426.80 | €544.15 +27.5% | 5.7% | €590.02 | €507.05 | €296.00 | 4 |
| Jan ’24 | €395.80 | €562.26 +42.1% | 5.9% | €611.20 | €525.25 | €290.60 | 4 |
| Dec ’23 | €402.50 | €598.81 +48.8% | 6.2% | €642.30 | €551.98 | €278.40 | 3 |
| Nov ’23 | €354.20 | €598.81 +69.1% | 6.2% | €642.30 | €551.98 | €257.80 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.74
7D
1.9%
1Y
-7.4%
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%